Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer

Kouji Izumi, Atsushi Mizokami, Hsiu Ping Lin, Hui Min Ho, Hiroaki Iwamoto, Aerken Maolake, Ariunbold Natsagdorj, Yasuhide Kitagawa, Yoshifumi Kadono, Hiroshi Miyamoto, Chiung Kuei Huang, Mikio Namiki, Wen Jye Lin

Research output: Contribution to journalArticle

Abstract

Prostate-specific antigen (PSA) is regarded as the most sensitive biomarker for prostate cancer. Although androgen/androgen receptor (AR) signaling promotes prostate cancer progression, suppression of AR signaling induces chemokine (CC motif) ligand 2 (CCL2), which enables prostate cancer cells to gain metastatic potential. AR-controlled PSA alone may be an unreliable biomarker for patients receiving androgen deprivation therapy. Therefore, we investigated the validity of CCL2 as a complementary biomarker to PSA for prostate cancer. Our in vitro approach of enriching for prostate cancer cells with higher migration potential showed that CCL2 activated cellular migration. Importantly, we found that CCL2 levels were significantly different between men (n = 379) with and without prostate cancer. Patients with CCL2 ≥ 320 pg/mL had worse overall survival and prostate cancer -specific survival than those with CCL2 <320 pg/mL. A novel risk classification was developed according to the risk factors CCL2 ≥ 320 pg/mL and PSA ≥ 100 ng/mL, and scores of 2, 1, and 0 were defined as poor, intermediate, and good risk, respectively, and clearly distinguished patient outcomes. CCL2 may serve as a novel biomarker for prostate cancer. The novel risk classification based on combining CCL2 and PSA is more reliable than using either alone.

Original languageEnglish (US)
Pages (from-to)8389-8398
Number of pages10
JournalOncotarget
Volume7
Issue number7
DOIs
StatePublished - 2016

Fingerprint

CC Chemokines
Prostatic Neoplasms
Biomarkers
Ligands
Prostate-Specific Antigen
Serum
Androgen Receptors
Androgens
Survival

Keywords

  • Androgen deprivation therapy
  • Biomarker
  • CCl2
  • Prostate cancer
  • Risk classification

ASJC Scopus subject areas

  • Oncology

Cite this

Izumi, K., Mizokami, A., Lin, H. P., Ho, H. M., Iwamoto, H., Maolake, A., ... Lin, W. J. (2016). Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer. Oncotarget, 7(7), 8389-8398. https://doi.org/10.18632/oncotarget.6690

Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer. / Izumi, Kouji; Mizokami, Atsushi; Lin, Hsiu Ping; Ho, Hui Min; Iwamoto, Hiroaki; Maolake, Aerken; Natsagdorj, Ariunbold; Kitagawa, Yasuhide; Kadono, Yoshifumi; Miyamoto, Hiroshi; Huang, Chiung Kuei; Namiki, Mikio; Lin, Wen Jye.

In: Oncotarget, Vol. 7, No. 7, 2016, p. 8389-8398.

Research output: Contribution to journalArticle

Izumi, K, Mizokami, A, Lin, HP, Ho, HM, Iwamoto, H, Maolake, A, Natsagdorj, A, Kitagawa, Y, Kadono, Y, Miyamoto, H, Huang, CK, Namiki, M & Lin, WJ 2016, 'Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer', Oncotarget, vol. 7, no. 7, pp. 8389-8398. https://doi.org/10.18632/oncotarget.6690
Izumi, Kouji ; Mizokami, Atsushi ; Lin, Hsiu Ping ; Ho, Hui Min ; Iwamoto, Hiroaki ; Maolake, Aerken ; Natsagdorj, Ariunbold ; Kitagawa, Yasuhide ; Kadono, Yoshifumi ; Miyamoto, Hiroshi ; Huang, Chiung Kuei ; Namiki, Mikio ; Lin, Wen Jye. / Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer. In: Oncotarget. 2016 ; Vol. 7, No. 7. pp. 8389-8398.
@article{b2f4ea6a063a4e26bd397e3363e9ef7d,
title = "Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer",
abstract = "Prostate-specific antigen (PSA) is regarded as the most sensitive biomarker for prostate cancer. Although androgen/androgen receptor (AR) signaling promotes prostate cancer progression, suppression of AR signaling induces chemokine (CC motif) ligand 2 (CCL2), which enables prostate cancer cells to gain metastatic potential. AR-controlled PSA alone may be an unreliable biomarker for patients receiving androgen deprivation therapy. Therefore, we investigated the validity of CCL2 as a complementary biomarker to PSA for prostate cancer. Our in vitro approach of enriching for prostate cancer cells with higher migration potential showed that CCL2 activated cellular migration. Importantly, we found that CCL2 levels were significantly different between men (n = 379) with and without prostate cancer. Patients with CCL2 ≥ 320 pg/mL had worse overall survival and prostate cancer -specific survival than those with CCL2 <320 pg/mL. A novel risk classification was developed according to the risk factors CCL2 ≥ 320 pg/mL and PSA ≥ 100 ng/mL, and scores of 2, 1, and 0 were defined as poor, intermediate, and good risk, respectively, and clearly distinguished patient outcomes. CCL2 may serve as a novel biomarker for prostate cancer. The novel risk classification based on combining CCL2 and PSA is more reliable than using either alone.",
keywords = "Androgen deprivation therapy, Biomarker, CCl2, Prostate cancer, Risk classification",
author = "Kouji Izumi and Atsushi Mizokami and Lin, {Hsiu Ping} and Ho, {Hui Min} and Hiroaki Iwamoto and Aerken Maolake and Ariunbold Natsagdorj and Yasuhide Kitagawa and Yoshifumi Kadono and Hiroshi Miyamoto and Huang, {Chiung Kuei} and Mikio Namiki and Lin, {Wen Jye}",
year = "2016",
doi = "10.18632/oncotarget.6690",
language = "English (US)",
volume = "7",
pages = "8389--8398",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "7",

}

TY - JOUR

T1 - Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer

AU - Izumi, Kouji

AU - Mizokami, Atsushi

AU - Lin, Hsiu Ping

AU - Ho, Hui Min

AU - Iwamoto, Hiroaki

AU - Maolake, Aerken

AU - Natsagdorj, Ariunbold

AU - Kitagawa, Yasuhide

AU - Kadono, Yoshifumi

AU - Miyamoto, Hiroshi

AU - Huang, Chiung Kuei

AU - Namiki, Mikio

AU - Lin, Wen Jye

PY - 2016

Y1 - 2016

N2 - Prostate-specific antigen (PSA) is regarded as the most sensitive biomarker for prostate cancer. Although androgen/androgen receptor (AR) signaling promotes prostate cancer progression, suppression of AR signaling induces chemokine (CC motif) ligand 2 (CCL2), which enables prostate cancer cells to gain metastatic potential. AR-controlled PSA alone may be an unreliable biomarker for patients receiving androgen deprivation therapy. Therefore, we investigated the validity of CCL2 as a complementary biomarker to PSA for prostate cancer. Our in vitro approach of enriching for prostate cancer cells with higher migration potential showed that CCL2 activated cellular migration. Importantly, we found that CCL2 levels were significantly different between men (n = 379) with and without prostate cancer. Patients with CCL2 ≥ 320 pg/mL had worse overall survival and prostate cancer -specific survival than those with CCL2 <320 pg/mL. A novel risk classification was developed according to the risk factors CCL2 ≥ 320 pg/mL and PSA ≥ 100 ng/mL, and scores of 2, 1, and 0 were defined as poor, intermediate, and good risk, respectively, and clearly distinguished patient outcomes. CCL2 may serve as a novel biomarker for prostate cancer. The novel risk classification based on combining CCL2 and PSA is more reliable than using either alone.

AB - Prostate-specific antigen (PSA) is regarded as the most sensitive biomarker for prostate cancer. Although androgen/androgen receptor (AR) signaling promotes prostate cancer progression, suppression of AR signaling induces chemokine (CC motif) ligand 2 (CCL2), which enables prostate cancer cells to gain metastatic potential. AR-controlled PSA alone may be an unreliable biomarker for patients receiving androgen deprivation therapy. Therefore, we investigated the validity of CCL2 as a complementary biomarker to PSA for prostate cancer. Our in vitro approach of enriching for prostate cancer cells with higher migration potential showed that CCL2 activated cellular migration. Importantly, we found that CCL2 levels were significantly different between men (n = 379) with and without prostate cancer. Patients with CCL2 ≥ 320 pg/mL had worse overall survival and prostate cancer -specific survival than those with CCL2 <320 pg/mL. A novel risk classification was developed according to the risk factors CCL2 ≥ 320 pg/mL and PSA ≥ 100 ng/mL, and scores of 2, 1, and 0 were defined as poor, intermediate, and good risk, respectively, and clearly distinguished patient outcomes. CCL2 may serve as a novel biomarker for prostate cancer. The novel risk classification based on combining CCL2 and PSA is more reliable than using either alone.

KW - Androgen deprivation therapy

KW - Biomarker

KW - CCl2

KW - Prostate cancer

KW - Risk classification

UR - http://www.scopus.com/inward/record.url?scp=84958794329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958794329&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.6690

DO - 10.18632/oncotarget.6690

M3 - Article

C2 - 26701731

AN - SCOPUS:84958794329

VL - 7

SP - 8389

EP - 8398

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 7

ER -